Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study


      • Reovirus when added to paclitaxel is not active in unselected patients with recurrent ovarian cancer.
      • Severe neutropenia and respiratory toxicity is more common with reovirus exposure.
      • The activity of weekly paclitaxel in recurrent ovarian cancer is confirmed.



      To assess whether the addition of oncolytic reovirus (Reolysin®) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer.

      Patients and methods

      Patients with recurrent or persistent epithelial ovarian, tubal, or peritoneal carcinoma, measurable or detectable disease, and three or fewer prior regimens were randomly assigned to paclitaxel (80 mg/m2 intravenously days 1, 8, and 15 every 4 weeks) or the combination of paclitaxel (80 mg/m2 intravenously days 1, 8, and 15) plus reovirus 3 × 1010 TCID50/day intravenously on days 1–5, both every 4 weeks until disease progression or toxicity. The primary end point was PFS. The study was designed with 80% power for a one-sided alternative at a 10% level of significance to detect a reduction in the hazard by 37.5%.


      The study accrued 108 patients, 100 of whom were evaluable for toxicity. Median PFS was 4.3 months for paclitaxel and 4.4 months for paclitaxel plus reovirus (hazard ratio, 1.11; 90% two-sided CI, 0.78 to 1.59; one-sided P = 0.687). The proportion responding (overall response rate) to paclitaxel was 20% among 45 patients with measurable disease receiving paclitaxel alone, and 17.4% among the 46 patients treated with the combination. The asymptotic relative probability of responding was 0.87 (90% CI, 0.42 to 1.79). Severe adverse events were more common in the combination regimen than in paclitaxel arm for severe neutropenia (grade ≥ 4, 12% versus 0%), and severe respiratory adverse events (grade ≥ 3, 25% versus 2%). No deaths were considered treatment related.


      The addition of reovirus to weekly paclitaxel in the treatment of women with recurrent or persistent ovarian, tubal or peritoneal cancer did not sufficiently reduce the hazard of progression or death to warrant further investigation.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cohn D.E.
        • Valmadre S.
        • Resnick K.E.
        • Eaton L.A.
        • Copeland L.J.
        • Fowler J.M.
        Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer.
        Gynecol. Oncol. 2006; 102: 134-139
        • Gynecologic Oncology Group
        • Markman M.
        • Blessing J.
        • Rubin S.C.
        • Connor J.
        • Hanjani P.
        • et al.
        Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
        Gynecol. Oncol. 2006; 101: 436-440
        • Gemignani M.L.
        • Schlaerth A.C.
        • Bogomolniy F.
        • Barakat R.R.
        • Lin O.
        • Soslow R.
        • et al.
        Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
        Gynecol. Oncol. 2003; 90: 378-381
        • Hirasawa K.
        • Nishikawa S.G.
        • Norman K.L.
        • Alain T.
        • Kossakowska A.
        • Lee P.W.
        Oncolytic reovirus against ovarian and colon cancer.
        Cancer Res. 2002; 62: 1696-1701
        • Cohn D.E.
        • Nuovo G.
        • Coffey M.C.
        • O’Malley D.
        • Villalona-Calero M.A.
        • Grever M.R.
        • Deam D.
        • Zwiebel J.A.
        • Phelps M.A.
        Phase I/II trial of reovirus serotype 3-dearing strain in patients with recurrent ovarian cancer.
        J. Clin. Oncol. 2010; 28TPS253
        • Phelps M.
        • Cohn D.E.
        • O’Malley D.M.
        • Wei L.
        • Wilkins D.
        • Campbell A.
        • Schaaf L.J.
        • Coffey M.C.
        • Villalona-Calero M.A.
        • Grever M.R.
        • Nuovo G.J.
        • Zwiebel J.A.
        Reovirus replication in ovarian and peritoneal tumors after intravenous administration.
        Cancer Res. 2010; 70: 2594
        • Heinemann L.
        • Simpson G.R.
        • Boxall A.
        • Kottke T.
        • Relph K.L.
        • Vile R.
        • et al.
        Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
        BMC Cancer. 2011; 11: 221
        • Comins C.
        • Spicer J.
        • Protheroe A.
        • Roulstone V.
        • Twigger K.
        • White C.M.
        • et al.
        REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
        Clin. Cancer Res. 2010; 16: 5564-5572
        • Sargent D.J.
        • Chan V.
        • Goldberg R.M.
        A three-outcome design for phase II clinical trials.
        Control. Clin. Trials. 2001; 22: 117-125
        • Lan K.K.G.
        • DeMets D.L.
        Discrete sequential boundaries for clinical trials.
        Biometrika. 1983; 70: 659-663
        • Gong J.
        • Sachdev E.
        • Mita A.C.
        • Mita M.M.
        Clinical development of reovirus for cancer therapy: an oncolytic virus with immune-mediated antitumor activity.
        World J. Methodol. 2016; 6: 25-42
        • Nuovo G.J.
        • Garofalo M.
        • Valeri N.
        • Roulstone V.
        • Volinia S.
        • Cohn D.E.
        • et al.
        Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples.
        Mod. Pathol. 2012; 25: 1333-1344
        • Marcato P.
        • Shmulevitz M.
        • Pan D.
        • Stoltz D.
        • Lee P.W.
        Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release.
        Mol. Ther. 2007; 15: 1522-1530
        • Gupta-Saraf P.
        • Miller C.L.
        HIF-1alpha downregulation and apoptosis in hypoxic prostate tumor cells infected with oncolytic mammalian orthoreovirus.
        Oncotarget. 2014; 5: 561-574
        • Paez-Ribes M.
        • Allen E.
        • Hudock J.
        • Takeda T.
        • Okuyama H.
        • Vinals F.
        • et al.
        Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
        Cancer Cell. 2009; 15: 220-231